Canagliflozin-associated diabetic ketoacidosis: a case report
Canagliflozin is a novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor approved for the management of diabetes. We report the presentation and management of two cases of canagliflozin associated diabetic ketoacidosis (DKA) and discuss the mechanism of canagliflozin associated DKA. Patient 1, a 5...
Gespeichert in:
| Veröffentlicht in: | Toxicology communications 2017-01, Vol.1 (1), p.2-5 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5 |
|---|---|
| container_issue | 1 |
| container_start_page | 2 |
| container_title | Toxicology communications |
| container_volume | 1 |
| creator | Chai, Peter R Bonney, Caitlin Blohm, Eike Boyer, Edward W Babu, Kavita M |
| description | Canagliflozin is a novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor approved for the management of diabetes. We report the presentation and management of two cases of canagliflozin associated diabetic ketoacidosis (DKA) and discuss the mechanism of canagliflozin associated DKA. Patient 1, a 55 year old woman maintained on canagliflozin for diabetes mellitus II presented to the emergency department (ED) with 24 hours of nausea and vomiting. She was diagnosed with DKA featuring hypotension, hyperglycemia, ketosis and acidosis. A second 54 year old man also maintained on canagliflozin for diabetes mellitus I presented to the ED with 24 hours of nausea and vomiting. He was diagnosed with DKA with similar manifestations as patient 1. Both patients underwent massive volume resuscitation and intravenous insulin therapy with resolution of ketosis and acidosis. By inhibiting SGLT-2, canagliflozin promotes glucosuria, which in turn can produce up to a 10% decrease in total plasma volume rendering patients maintained on canagliflozin susceptible to dehydration. Inhibition of SGLT-2 also leads to glucagon secretion, which in the volume deplete individual, can exacerbate DKA. Physicians should be aware of the rapid onset of DKA in patients maintained on canagliflozin after just minor additional fluid losses. |
| doi_str_mv | 10.1080/24734306.2017.1331604 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6029867</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2196546416</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2844-fe7623545712b11c9230132d5b5d33797c1e5fd0cc3b9613b69efd473212220d3</originalsourceid><addsrcrecordid>eNpdkdtKAzEQhoMoVmofQVnwxputOWcjKEjxBAVv9Dpkk2xN3W5qsivo07ulB6pXGTLf_MzwAXCG4BjBAl5hKgglkI8xRGKMCEEc0gNwsvrPV43DvXoARinNIezRgrCCHoMBllIUiPETcDPRjZ7VvqrDj29ynVIwXrfOZtbr0rXeZB-uDdp4G5JP15nOjE4ui24ZYnsKjipdJzfavEPw9nD_OnnKpy-Pz5O7aW5wQWleOcExYZQJhEuEjMQEIoItK5klREhhkGOVhcaQUnJESi5dZfv9McIYQ0uG4Hadu-zKhbPGNW3UtVpGv9DxWwXt1d9O49_VLHwpDrEsuOgDLjcBMXx2LrVq4ZNxda0bF7qkMOScCkkY7tGLf-g8dLHpz1MYSc4op4j3FFtTJoaUoqt2yyCoVo7U1pFaOVIbR_3c-f4lu6mtEfIL_-mK1Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2196546416</pqid></control><display><type>article</type><title>Canagliflozin-associated diabetic ketoacidosis: a case report</title><source>Taylor & Francis Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Chai, Peter R ; Bonney, Caitlin ; Blohm, Eike ; Boyer, Edward W ; Babu, Kavita M</creator><creatorcontrib>Chai, Peter R ; Bonney, Caitlin ; Blohm, Eike ; Boyer, Edward W ; Babu, Kavita M</creatorcontrib><description>Canagliflozin is a novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor approved for the management of diabetes. We report the presentation and management of two cases of canagliflozin associated diabetic ketoacidosis (DKA) and discuss the mechanism of canagliflozin associated DKA. Patient 1, a 55 year old woman maintained on canagliflozin for diabetes mellitus II presented to the emergency department (ED) with 24 hours of nausea and vomiting. She was diagnosed with DKA featuring hypotension, hyperglycemia, ketosis and acidosis. A second 54 year old man also maintained on canagliflozin for diabetes mellitus I presented to the ED with 24 hours of nausea and vomiting. He was diagnosed with DKA with similar manifestations as patient 1. Both patients underwent massive volume resuscitation and intravenous insulin therapy with resolution of ketosis and acidosis. By inhibiting SGLT-2, canagliflozin promotes glucosuria, which in turn can produce up to a 10% decrease in total plasma volume rendering patients maintained on canagliflozin susceptible to dehydration. Inhibition of SGLT-2 also leads to glucagon secretion, which in the volume deplete individual, can exacerbate DKA. Physicians should be aware of the rapid onset of DKA in patients maintained on canagliflozin after just minor additional fluid losses.</description><identifier>ISSN: 2473-4306</identifier><identifier>EISSN: 2473-4306</identifier><identifier>DOI: 10.1080/24734306.2017.1331604</identifier><identifier>PMID: 29978156</identifier><language>eng</language><publisher>England: Taylor & Francis Ltd</publisher><subject>Acidosis ; Case reports ; Dehydration ; Diabetes ; Diabetes mellitus ; Drug therapy ; Glucagon ; Glucose ; Hyperglycemia ; Hypotension ; Insulin ; Intravenous administration ; Ketoacidosis ; Na+/glucose cotransporter ; Nausea ; Patients ; Side effects ; Toxicology ; Vomiting</subject><ispartof>Toxicology communications, 2017-01, Vol.1 (1), p.2-5</ispartof><rights>2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2844-fe7623545712b11c9230132d5b5d33797c1e5fd0cc3b9613b69efd473212220d3</citedby><cites>FETCH-LOGICAL-c2844-fe7623545712b11c9230132d5b5d33797c1e5fd0cc3b9613b69efd473212220d3</cites><orcidid>0000-0003-0955-4117 ; 0000-0002-3454-1310</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,864,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29978156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chai, Peter R</creatorcontrib><creatorcontrib>Bonney, Caitlin</creatorcontrib><creatorcontrib>Blohm, Eike</creatorcontrib><creatorcontrib>Boyer, Edward W</creatorcontrib><creatorcontrib>Babu, Kavita M</creatorcontrib><title>Canagliflozin-associated diabetic ketoacidosis: a case report</title><title>Toxicology communications</title><addtitle>Toxicol Commun</addtitle><description>Canagliflozin is a novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor approved for the management of diabetes. We report the presentation and management of two cases of canagliflozin associated diabetic ketoacidosis (DKA) and discuss the mechanism of canagliflozin associated DKA. Patient 1, a 55 year old woman maintained on canagliflozin for diabetes mellitus II presented to the emergency department (ED) with 24 hours of nausea and vomiting. She was diagnosed with DKA featuring hypotension, hyperglycemia, ketosis and acidosis. A second 54 year old man also maintained on canagliflozin for diabetes mellitus I presented to the ED with 24 hours of nausea and vomiting. He was diagnosed with DKA with similar manifestations as patient 1. Both patients underwent massive volume resuscitation and intravenous insulin therapy with resolution of ketosis and acidosis. By inhibiting SGLT-2, canagliflozin promotes glucosuria, which in turn can produce up to a 10% decrease in total plasma volume rendering patients maintained on canagliflozin susceptible to dehydration. Inhibition of SGLT-2 also leads to glucagon secretion, which in the volume deplete individual, can exacerbate DKA. Physicians should be aware of the rapid onset of DKA in patients maintained on canagliflozin after just minor additional fluid losses.</description><subject>Acidosis</subject><subject>Case reports</subject><subject>Dehydration</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Drug therapy</subject><subject>Glucagon</subject><subject>Glucose</subject><subject>Hyperglycemia</subject><subject>Hypotension</subject><subject>Insulin</subject><subject>Intravenous administration</subject><subject>Ketoacidosis</subject><subject>Na+/glucose cotransporter</subject><subject>Nausea</subject><subject>Patients</subject><subject>Side effects</subject><subject>Toxicology</subject><subject>Vomiting</subject><issn>2473-4306</issn><issn>2473-4306</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkdtKAzEQhoMoVmofQVnwxputOWcjKEjxBAVv9Dpkk2xN3W5qsivo07ulB6pXGTLf_MzwAXCG4BjBAl5hKgglkI8xRGKMCEEc0gNwsvrPV43DvXoARinNIezRgrCCHoMBllIUiPETcDPRjZ7VvqrDj29ynVIwXrfOZtbr0rXeZB-uDdp4G5JP15nOjE4ui24ZYnsKjipdJzfavEPw9nD_OnnKpy-Pz5O7aW5wQWleOcExYZQJhEuEjMQEIoItK5klREhhkGOVhcaQUnJESi5dZfv9McIYQ0uG4Hadu-zKhbPGNW3UtVpGv9DxWwXt1d9O49_VLHwpDrEsuOgDLjcBMXx2LrVq4ZNxda0bF7qkMOScCkkY7tGLf-g8dLHpz1MYSc4op4j3FFtTJoaUoqt2yyCoVo7U1pFaOVIbR_3c-f4lu6mtEfIL_-mK1Q</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Chai, Peter R</creator><creator>Bonney, Caitlin</creator><creator>Blohm, Eike</creator><creator>Boyer, Edward W</creator><creator>Babu, Kavita M</creator><general>Taylor & Francis Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FD</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0955-4117</orcidid><orcidid>https://orcid.org/0000-0002-3454-1310</orcidid></search><sort><creationdate>20170101</creationdate><title>Canagliflozin-associated diabetic ketoacidosis: a case report</title><author>Chai, Peter R ; Bonney, Caitlin ; Blohm, Eike ; Boyer, Edward W ; Babu, Kavita M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2844-fe7623545712b11c9230132d5b5d33797c1e5fd0cc3b9613b69efd473212220d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acidosis</topic><topic>Case reports</topic><topic>Dehydration</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Drug therapy</topic><topic>Glucagon</topic><topic>Glucose</topic><topic>Hyperglycemia</topic><topic>Hypotension</topic><topic>Insulin</topic><topic>Intravenous administration</topic><topic>Ketoacidosis</topic><topic>Na+/glucose cotransporter</topic><topic>Nausea</topic><topic>Patients</topic><topic>Side effects</topic><topic>Toxicology</topic><topic>Vomiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chai, Peter R</creatorcontrib><creatorcontrib>Bonney, Caitlin</creatorcontrib><creatorcontrib>Blohm, Eike</creatorcontrib><creatorcontrib>Boyer, Edward W</creatorcontrib><creatorcontrib>Babu, Kavita M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Toxicology communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chai, Peter R</au><au>Bonney, Caitlin</au><au>Blohm, Eike</au><au>Boyer, Edward W</au><au>Babu, Kavita M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Canagliflozin-associated diabetic ketoacidosis: a case report</atitle><jtitle>Toxicology communications</jtitle><addtitle>Toxicol Commun</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>1</volume><issue>1</issue><spage>2</spage><epage>5</epage><pages>2-5</pages><issn>2473-4306</issn><eissn>2473-4306</eissn><abstract>Canagliflozin is a novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor approved for the management of diabetes. We report the presentation and management of two cases of canagliflozin associated diabetic ketoacidosis (DKA) and discuss the mechanism of canagliflozin associated DKA. Patient 1, a 55 year old woman maintained on canagliflozin for diabetes mellitus II presented to the emergency department (ED) with 24 hours of nausea and vomiting. She was diagnosed with DKA featuring hypotension, hyperglycemia, ketosis and acidosis. A second 54 year old man also maintained on canagliflozin for diabetes mellitus I presented to the ED with 24 hours of nausea and vomiting. He was diagnosed with DKA with similar manifestations as patient 1. Both patients underwent massive volume resuscitation and intravenous insulin therapy with resolution of ketosis and acidosis. By inhibiting SGLT-2, canagliflozin promotes glucosuria, which in turn can produce up to a 10% decrease in total plasma volume rendering patients maintained on canagliflozin susceptible to dehydration. Inhibition of SGLT-2 also leads to glucagon secretion, which in the volume deplete individual, can exacerbate DKA. Physicians should be aware of the rapid onset of DKA in patients maintained on canagliflozin after just minor additional fluid losses.</abstract><cop>England</cop><pub>Taylor & Francis Ltd</pub><pmid>29978156</pmid><doi>10.1080/24734306.2017.1331604</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-0955-4117</orcidid><orcidid>https://orcid.org/0000-0002-3454-1310</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2473-4306 |
| ispartof | Toxicology communications, 2017-01, Vol.1 (1), p.2-5 |
| issn | 2473-4306 2473-4306 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6029867 |
| source | Taylor & Francis Open Access; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Acidosis Case reports Dehydration Diabetes Diabetes mellitus Drug therapy Glucagon Glucose Hyperglycemia Hypotension Insulin Intravenous administration Ketoacidosis Na+/glucose cotransporter Nausea Patients Side effects Toxicology Vomiting |
| title | Canagliflozin-associated diabetic ketoacidosis: a case report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T20%3A29%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Canagliflozin-associated%20diabetic%20ketoacidosis:%20a%20case%20report&rft.jtitle=Toxicology%20communications&rft.au=Chai,%20Peter%20R&rft.date=2017-01-01&rft.volume=1&rft.issue=1&rft.spage=2&rft.epage=5&rft.pages=2-5&rft.issn=2473-4306&rft.eissn=2473-4306&rft_id=info:doi/10.1080/24734306.2017.1331604&rft_dat=%3Cproquest_pubme%3E2196546416%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2196546416&rft_id=info:pmid/29978156&rfr_iscdi=true |